Abstract
Genome-wide association studies (GWAS) have identified 12 epithelial ovarian cancer (EOC) susceptibility alleles. The pattern of association at these loci is consistent in BRCA1 and BRCA2 mutation carriers who are at high risk of EOC. After imputation to 1000 Genomes Project data, we assessed associations of 11 million genetic variants with EOC risk from 15,437 cases unselected for family history and 30,845 controls and from 15,252 BRCA1 mutation carriers and 8,211 BRCA2 mutation carriers (3,096 with ovarian cancer), and we combined the results in a meta-analysis. This new study design yielded increased statistical power, leading to the discovery of six new EOC susceptibility loci. Variants at 1p36 (nearest gene, WNT4), 4q26 (SYNPO2), 9q34.2 (ABO) and 17q11.2 (ATAD5) were associated with EOC risk, and at 1p34.3 (RSPO1) and 6p22.1 (GPX6) variants were specifically associated with the serous EOC subtype, all with P < 5 × 10−8. Incorporating these variants into risk assessment tools will improve clinical risk predictions for BRCA1 and BRCA2 mutation carriers.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Synaptopodin-2: a potential tumor suppressor
Cancer Cell International Open Access 07 August 2023
-
Implementation of individualised polygenic risk score analysis: a test case of a family of four
BMC Medical Genomics Open Access 03 October 2022
-
The role of R-spondin proteins in cancer biology
Oncogene Open Access 18 October 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Auranen, A. et al. Cancer incidence in the first-degree relatives of ovarian cancer patients. Br. J. Cancer 74, 280–284 (1996).
Stratton, J.F., Pharoah, P., Smith, S.K., Easton, D. & Ponder, B.A. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br. J. Obstet. Gynaecol. 105, 493–499 (1998).
Jervis, S. et al. Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. J. Med. Genet. 51, 108–113 (2014).
Bolton, K.L. et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat. Genet. 42, 880–884 (2010).
Goode, E.L. et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat. Genet. 42, 874–879 (2010).
Song, H. et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat. Genet. 41, 996–1000 (2009).
Pharoah, P.D. et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat. Genet. 45, 362–370 (2013).
Permuth-Wey, J. et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat. Commun. 4, 1627 (2013).
Bojesen, S.E. et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat. Genet. 45, 371–384 (2013).
Couch, F.J. et al. Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol. Biomarkers Prev. 21, 645–657 (2012).
Ramus, S.J. et al. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum. Mutat. 33, 690–702 (2012).
Ramus, S.J. et al. Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 103, 105–116 (2011).
Couch, F.J. et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet. 9, e1003212 (2013).
Bolton, K.L., Ganda, C., Berchuck, A., Pharaoh, P.D. & Gayther, S.A. Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the Ovarian Cancer Association Consortium (OCAC). J. Intern. Med. 271, 366–378 (2012).
Chenevix-Trench, G. et al. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res. 9, 104 (2007).
Gaudet, M.M. et al. Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet. 9, e1003173 (2013).
1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56–65 (2012).
Barnes, D.R. et al. Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations. Genet. Epidemiol. 36, 274–291 (2012).
Bourguignon, L.Y., Gilad, E., Rothman, K. & Peyrollier, K. Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1/estrogen receptor transcriptional activation, and ovarian cancer progression. J. Biol. Chem. 280, 11961–11972 (2005).
Zuo, Y., Wu, Y. & Chakraborty, C. Cdc42 negatively regulates intrinsic migration of highly aggressive breast cancer cells. J. Cell. Physiol. 227, 1399–1407 (2012).
Pagliardini, L. et al. An Italian association study and meta-analysis with previous GWAS confirm WNT4, CDKN2BAS and FN1 as the first identified susceptibility loci for endometriosis. J. Med. Genet. 50, 43–46 (2013).
Pearce, C.L. et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 13, 385–394 (2012).
Tomaselli, S. et al. Human RSPO1/R-spondin1 is expressed during early ovary development and augments β-catenin signaling. PLoS ONE 6, e16366 (2011).
Parma, P. et al. R-spondin1 is essential in sex determination, skin differentiation and malignancy. Nat. Genet. 38, 1304–1309 (2006).
Tomizuka, K. et al. R-spondin1 plays an essential role in ovarian development through positively regulating Wnt-4 signaling. Hum. Mol. Genet. 17, 1278–1291 (2008).
De Ganck, A. et al. Multiple isoforms of the tumor suppressor myopodin are simultaneously transcribed in cancer cells. Biochem. Biophys. Res. Commun. 370, 269–273 (2008).
Jing, L. et al. Expression of myopodin induces suppression of tumor growth and metastasis. Am. J. Pathol. 164, 1799–1806 (2004).
Lin, F. et al. Myopodin, a synaptopodin homologue, is frequently deleted in invasive prostate cancers. Am. J. Pathol. 159, 1603–1612 (2001).
Sanchez-Carbayo, M., Schwarz, K., Charytonowicz, E., Cordon-Cardo, C. & Mundel, P. Tumor suppressor role for myopodin in bladder cancer: loss of nuclear expression of myopodin is cell-cycle dependent and predicts clinical outcome. Oncogene 22, 5298–5305 (2003).
Yu, Y.P. & Luo, J.H. Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin. Cancer Res. 66, 7414–7419 (2006).
Amundadottir, L. et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat. Genet. 41, 986–990 (2009).
Rummel, S., Shriver, C.D. & Ellsworth, R.E. Relationships between the ABO blood group SNP rs505922 and breast cancer phenotypes: a genotype-phenotype correlation study. BMC Med. Genet. 13, 41 (2012).
Poole, E.M. et al. ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium. Cancer Causes Control 23, 1805–1810 (2012).
Sikdar, N. et al. DNA damage responses by human ELG1 in S phase are important to maintain genomic integrity. Cell Cycle 8, 3199–3207 (2009).
Bell, D.W. et al. Predisposition to cancer caused by genetic and functional defects of mammalian Atad5. PLoS Genet. 7, e1002245 (2011).
Lee, K.Y. et al. Human ELG1 regulates the level of ubiquitinated proliferating cell nuclear antigen (PCNA) through Its interactions with PCNA and USP1. J. Biol. Chem. 285, 10362–10369 (2010).
Wacholder, S., Han, S.S. & Weinberg, C.R. Inference from a multiplicative model of joint genetic effects for ovarian cancer risk. J. Natl. Cancer Inst. 103, 82–83 (2011).
Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934–947 (2013).
Permuth-Wey, J. et al. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res. 71, 3896–3903 (2011).
Delaneau, O., Marchini, J. & Zagury, J.F. A linear complexity phasing method for thousands of genomes. Nat. Methods 9, 179–181 (2012).
Howie, B.N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 5, e1000529 (2009).
Antoniou, A.C. et al. RAD51 135G→C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am. J. Hum. Genet. 81, 1186–1200 (2007).
Antoniou, A.C. et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat. Genet. 42, 885–892 (2010).
R: A Language and Environment for Statistical Computing v. 3.0.1 (R Foundation for Statistical Computing, 2013).
Mavaddat, N. et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol. Biomarkers Prev. 21, 134–147 (2012).
Lakhani, S.R. et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin. Cancer Res. 10, 2473–2481 (2004).
Rubin, S.C. et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N. Engl. J. Med. 335, 1413–1416 (1996).
Maehle, L. et al. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers. Clin. Cancer Res. 14, 7569–7573 (2008).
Shaw, P.A. et al. Histopathologic features of genetically determined ovarian cancer. Int. J. Gynecol. Pathol. 21, 407–411 (2002).
Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–2191 (2010).
Udler, M.S., Tyrer, J. & Easton, D.F. Evaluating the power to discriminate between highly correlated SNPs in genetic association studies. Genet. Epidemiol. 34, 463–468 (2010).
Reumers, J. et al. Joint annotation of coding and non-coding single nucleotide polymorphisms and mutations in the SNPeffect and PupaSuite databases. Nucleic Acids Res. 36, D825–D829 (2008).
Conde, L. et al. PupaSuite: finding functional single nucleotide polymorphisms for large-scale genotyping purposes. Nucleic Acids Res. 34, W621–W625 (2006).
Li, N.F. et al. A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. Lab. Invest. 84, 923–931 (2004).
Fotheringham, S., Levanon, K. & Drapkin, R. Ex vivo culture of primary human fallopian tube epithelial cells. J. Vis. Exp. 51, 2728 (2011).
Li, Q. et al. Expressopn QTL–based analyses reveal candidate causal genes and loci across five tumor types. Hum. Mol. Genet. 23, 5294–5302 (2014).
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).
Forbes, S.A. et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr. Protoc. Hum. Genet. Chapter 10, Unit 10.11 (2008).
Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
Lawrenson, K. et al. Senescent fibroblasts promote neoplastic transformation of partially transformed ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer. Neoplasia 12, 317–325 (2010).
Acknowledgements
We thank all the individuals who took part in this study and all the researchers, clinicians, and technical and administrative staff who made possible the many studies contributing to this work (a full list is provided in the Supplementary Note), including X.Q. Chen for iPLEX genotyping. The COGS project is funded through a European Commission Seventh Framework Programme grant (agreement number 223175-HEALTH-F2-2009-223175). CIMBA data management and data analysis were supported by Cancer Research UK grants C12292/A11174 and C1287/A10118. The Ovarian Cancer Association Consortium (OCAC) is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith (PPD/RPCI.07). Scientific development and funding for this project were in part supported by the US National Cancer Institute GAME-ON Post-GWAS Initiative (U19-CA148112). This study made use of data generated by the Wellcome Trust Case Control Consortium. Funding for the project was provided by the Wellcome Trust under award 076113. The results published here are in part based on data generated by The Cancer Genome Atlas (TCGA) Pilot Project established by the US National Cancer Institute and US National Human Genome Research Institute (database of Genotypes and Phenotypes (dbGaP) accession phs000178.v8.p7). The cBio Portal is developed and maintained by the Computational Biology Center at the Memorial Sloan-Kettering Cancer Center. S. Healey is supported by a National Health and Medical Research Council of Australia Program Grant to G.C.-T. Details of the funding of individual investigators and studies are provided in the Supplementary Note. A full list of the investigators who contributed to the generation of the data is available on the CIMBA website (see URLs).
Author information
Authors and Affiliations
Consortia
Contributions
Writing group: K.B.K., A.C.A., G.C.-T., S.J.R., J. Beesley, P.P.P., S.G. Performed statistical analyses for CIMBA: K.B.K. Performed statistical analyses for OCAC: J.T. Performed the meta-analyses: K.B.K. CIMBA database management: L.M. and D.B. Supervised CIMBA statistical analyses, meta-analyses and CIMBA data management: A.C.A. Supervised OCAC statistical analyses: P.P.P. Initiated and coordinated CIMBA: G.C.-T. Coordinated OCAC: A. Berchuck and P.P.P. Conceived and coordinated the synthesis of the iCOGS array: D.F.E. Coordinated iCOGS genotyping: J.S., K. Offit, F.J.C. iCOGS genotyping, calling and quality control: J.M. Cunningham, J.D., P.S., D.F.E., K.B.K., J.T., P.P.P., A.C.A., G.C.-T. Programming support: A. Lee. Provided DNA samples and/or phenotypic data: S.J.R., J.T., A. Lee, H.C.S., K.L., S. Healey, J.M.L., T.J.S., Y.G.L., T.P., Y.B., Q.L., S.C., D.H., A. Miron, M. Southey, M.B.T., D.E.G., S.S.B., R.J., C.M.D., E.J.v.R., S.L.N., Y.C.D., T.V.O.H., L.J., A.-M.G., B.E., J.D., J. Benitez, A.O., M.J.G., I. Komenaka, J.N.W., P.G., P.P., L. Bernard, A.V., B.B., B.P., S. Manoukian, P.R., L.P., L.O., F.F., I. Konstantopoulou, J. Garber, D.F., J. Perkins, R.P., S.E., EMBRACE, A.K.G., R.K.S., A. Meindl, C.E., C.S., O.M.S., GEMO, F.D., S. Mazoyer, D.S.-L., K. Claes, K.D.L., J. Kirk, G.C.R., M. Piedmonte, D.M.O., M.d.l.H., T.C., K.A., H. Nevanlinna, J.M. Collée, M.A. Rookus, J.C.O., F.B.L.H., HEBON, E.O., O.D., I.B., J. Brunet, C.L., M.A.P., A. Jakubowska, J. Gronwald, J. Lubinski, G.S., R.B.B., M. Plante, J.S., P.S., M.M., S. Tognazzo, M.R.T., KConFab, V.S.P., X. Wang, N.L., C.I.S., N.K., J.V., C.A.A., G.P., A. Berger, C.F.S., M.-K.T., C.M.P., M.H.G., P.L.M., G.R., A.M.M., S. Tchatchou, I.L.A., G.G., A.E.T., U.B.J., T.A.K., M. Thomassen, A. Bojesen, J.Z., E.F., Y.L., M. Soller, A. Liljegren, B.A., Z.E., M.S.-A., O.I.O., R.L.N., T.R.R., K.L.N., S.M.D., K.H.L., B.Y.K., C.W., J. Lester, Australian Cancer Society, Australian Ovarian Cancer Study Group, A.H., A.B.E., M.W.B., P.A.F., D. Lambrechts, E.V.N., I.V., S. Lambrechts, E.D., J.A.D., K.G.W., M.A. Rossing, A.R., J.C.-C., S.W.-G., U.E., K.B.M., K. Odunsi, L.S., S. Lele, L.R.W., M.T.G., P.J.T., Y.B.S., I.B.R., M.D., P. Hillemanns, T.D., N.A., N.B., A. Leminen, L.M.P., R.B., F.M., J.L.K., R.P.E., R.B.N., A.d.B., F.H., I.S., P. Harter, K.M., S. Hosono, S.O., A. Jensen, S.K.K., E.H., H.N.H., M.A.N.A., S.-H.T., Y.-L.W., B.L.F., E.L.G., J.M. Cunningham, R.A.V., F.B., G.G.G., D. Liang, M.A.T.H., X. Wu, D.A.L., M.B., A. Berchuck, E.S.I., J.M.S., P.C., R.P.W., D.W.C., K.L.T., E.M.P., S.S.T., E.V.B., I.O., S.H.O., C.K., H.B.S., I.L.T., L. Bjorge, A.M.v.A., K.K.H.A., L.A.K., L.F.A.G.M., M.K., A.B.-W., L.E.K., L.S.C., N.D.L., C.C., H.Y., J. Lissowska, L.A.B., N.W., C.H., L.L., L.N., H.B., H.S., D.E., I.G.C., I.M., J. Paul, K. Carty, N.S., R.G., A.S.W., J.H.R., V.M., W.S., B.-T.J., W.Z., X.-O.S., Y.-T.G., B.R., H.A.R., J.R.M., S.A.N., A.N.M., A.C., H.-Y.L., J.P.-W., T.A.S., Y.-Y.T., Z.C., A.Z., H.A.-C., A.G.-M., U.M., P. Harrington, A.W.L., A.H.W., C.L.P., G.C., M.C.P., A.D.-M., A.T., I.K.R., J. Kupryjanczyk, M.F., H. Noushmehr, L.T., N.T., U.H., C.I., M. Tischkowitz, E.N.I., M.A.C., D.F.E., K. Offit, F.J.C., S.G., P.P.P., A.C.A., G.C.-T. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Additional information
A full list of members appears in the Supplementary Note.
A full list of members appears in the Supplementary Note.
A full list of members appears in the Supplementary Note.
A full list of members appears in the Supplementary Note.
A full list of members appears in the Supplementary Note.
A full list of members appears in the Supplementary Note.
A full list of members appears in the Supplementary Note.
A full list of members appears in the Supplementary Note.
Integrated supplementary information
Supplementary Figure 1 Imputation accuracy distribution.
Histogram showing the distribution of imputation accuracy estimates r2 in the first genotype imputation on the 1000 Genomes Project data v3 for SNPs with MAF > 0.05 (a,c,e) and for SNPs with MAF ≤ 0.05 (b,d,f) in OCAC-iCOGS (a,b), BRCA1 mutation carriers (c,d) and BRCA2 mutation carriers (e,f).
Supplementary Figure 2 Imputation accuracy distribution.
Histogram showing the distribution of imputation accuracy estimates r2 in the first genotype imputation on the 1000 Genomes Project data v3 for SNPs with MAF > 0.05 (a,c,e) and for SNPs with MAF ≤ 0.05 (b,d,f) in the UK GWAS (a,b), the US GWAS (c,d) and the Mayo GWAS (e,f).
Supplementary Figure 3 Quantile-quantile plot for genetic variants from the genotype imputation.
The column on the left shows all variants, and the right column shows variants not located in regions previously known to be associated with invasive ovarian cancer.
Supplementary Figure 4 Meta-analysis risk associations.
Manhattan plots showing the meta-analysis associations of genetic variants with risk of any subtype of ovarian cancer (a,b) and serous subtype ovarian cancer (c,d) for all genetic variants available after the first imputation (a,c) and after excluding SNPs located within known ovarian cancer susceptibility loci (b,d).
Supplementary Figure 5 Regional association plots for each novel locus based on the meta-analysis.
For 17q11.2, the meta-analysis was based on OCAC and BRCA2 mutation carriers only. For 1p34.3 and 6p22.1, the OCAC analysis was based on serous ovarian cancer. SNPs genotyped by the iCOGS array are shown in magenta, and imputed SNPs are shown in black.
Supplementary Figure 6 Ovarian cancer susceptibility loci at chromosome 1 and chromosome 4.
The Manhattan plot depicts the strength of association between all imputed and genotyped SNPs across the regions at chromosome 1 (a) and chromosome 4 (b). The dotted line represents the genome-wide significance level 5 × 10−8. FAIRE-seq data revealing potential regulatory regions in ovarian and fallopian tube cells are depicted as black bars. Additional tracks show genes and enhancers in ovary as described in Hnisz et al.38. Positions of SNPs for which imputation r2 < 0.3 and/or minor allele frequency < 0.005 are shown in the bottom track as ‘untyped’ SNPs.
Supplementary Figure 7 Ovarian cancer susceptibility loci at chromosome 6 and chromosome 9.
The Manhattan plot depicts the strength of association between all imputed and genotyped SNPs across the regions at chromosome 6 (a) and chromosome 9 (b). The dotted line represents the genome-wide significance level 5 × 10−8. FAIRE-seq data revealing potential regulatory regions in ovarian and fallopian tube cells are depicted as black bars. Additional tracks show genes and enhancers in ovary as described in Hnisz et al.38. Positions of SNPs for which imputation r2 < 0.3 and/or minor allele frequency < 0.005 are shown in the bottom track as ‘untyped’ SNPs.
Supplementary Figure 8 Ovarian cancer susceptibility locus at chromosome 17.
The Manhattan plot depicts the strength of association between all imputed and genotyped SNPs across the regions at chromosome 17. The dotted line represents the genome-wide significance level 5 × 10−8. FAIRE-seq data revealing potential regulatory regions in ovarian and fallopian tube cells are depicted as black bars. Additional tracks show genes and enhancers in ovary as described in Hnisz et al.38. Positions of SNPs for which imputation r2 < 0.3 and/or minor allele frequency < 0.005 are shown in the bottom track as ‘untyped’ SNPs.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–8, Supplementary Tables 1–12 and Supplementary Note. (PDF 2825 kb)
Rights and permissions
About this article
Cite this article
Kuchenbaecker, K., Ramus, S., Tyrer, J. et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet 47, 164–171 (2015). https://doi.org/10.1038/ng.3185
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.3185
This article is cited by
-
Synaptopodin-2: a potential tumor suppressor
Cancer Cell International (2023)
-
Implementation of individualised polygenic risk score analysis: a test case of a family of four
BMC Medical Genomics (2022)
-
Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer